FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roger Illingworth

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Heterozygote

Procedures

Drug Therapy, Combination

Co-author Network

Publications

TOP 3
Anuradha S Pappu; William E Connor; Louise S Merkens; Julia M Jordan; Jennifer A Penfield; D Roger Illingworth; Robert D Steiner
Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol.
Joanne M Donovan; K Von Bergmann; Kenneth D R Setchell; Jonathan L Isaacsohn; Anuradha S Pappu; D Roger Illingworth; T Olson; Steven K Burke
Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.
Rajesh G Mishra; Kent Hermsmeyer; Koichi Miyagawa; Philip M Sarrel; Barry T Uchida; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Frank J Nordt
Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roger Illingworth (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Anuradha S Pappu; William E Connor; Louise S Merkens; Julia M Jordan; Jennifer A Penfield; D Roger Illingworth; Robert D Steiner
Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol.
Journal of lipid research 2006;47(12):2789-98.
2005: Joanne M Donovan; K Von Bergmann; Kenneth D R Setchell; Jonathan L Isaacsohn; Anuradha S Pappu; D Roger Illingworth; T Olson; Steven K Burke
Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.
Digestive diseases and sciences 2005;50(7):1232-8.
2005: Rajesh G Mishra; Kent Hermsmeyer; Koichi Miyagawa; Philip M Sarrel; Barry T Uchida; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Frank J Nordt
Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys.
The Journal of clinical endocrinology and metabolism 2005;90(6):3706-14.
2004: Kent Hermsmeyer; Rajesh G Mishra; Dusan Pavcnik; Barry T Uchida; Michael K Axthelm; Frank Z Stanczyk; Kenneth A Burry; D Roger Illingworth; Carlos Juan; Frank J Nordt
Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone.
Arteriosclerosis, thrombosis, and vascular biology 2004;24(5):955-61.
2003: D Roger Illingworth
Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines.
Cardiology clinics 2003;21(3):363-75.
2003: Anuradha S Pappu; Sandra P Bacon; D Roger Illingworth
Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
The Journal of laboratory and clinical medicine 2003;141(4):250-6.
2002: Anuradha S Pappu; D Roger Illingworth
The effects of lovastatin and simvastatin on the diurnal periodicity of plasma mevalonate concentrations in patients with heterozygous familial hypercholesterolemia.
Atherosclerosis 2002;165(1):137-44.
2002: Anuradha S Pappu; Robert D Steiner; Sonja L Connor; Donna P Flavell; Don S Lin; Lauren Hatcher; D Roger Illingworth; William E Connor
Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion.
Journal of lipid research 2002;43(10):1661-9.
2001: David J A Jenkins; Cyril W C Kendall; David Popovich; Edward Vidgen; Christine Mehling; Vladimir Vuksan; TP Ransom; A Venket Rao; R Rosenberg-Zand; N Tariq; Paul N Corey; Peter J H Jones; M Raeini; Jon A Story; Emily J Furumoto; D Roger Illingworth; Anuradha S Pappu; Philip W Connelly
Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function.
Metabolism: clinical and experimental 2001;50(4):494-503.
2001: D Roger Illingworth; John R Crouse; Donald B Hunninghake; Michael H Davidson; Ivan D Escobar; A F Stalenhoef; G Paragh; P T Ma; Mingyue Liu; MR Melino; L O'Grady; Michele Mercuri; Yale B Mitchel
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Current medical research and opinion 2001;17(1):43-50.
2001: D Roger Illingworth; Jonathan A Tobert
HMG-CoA reductase inhibitors.
Advances in protein chemistry 2001;56():77-114.
2000: Frederick J Raal; Anuradha S Pappu; D Roger Illingworth; GJ Pilcher; Adrian David Marais; Jean Catherine Firth; Maritha J Kotze; Therese Heinonen; DM Black
Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.
Atherosclerosis 2000;150(2):421-8.
2000: D Roger Illingworth
Management of hypercholesterolemia.
The Medical clinics of North America 2000;84(1):23-42.
1999: J P O'Malley; Cheryl L Maslen; D Roger Illingworth
Angiotensin-converting enzyme and cardiovascular disease risk.
Current opinion in lipidology 1999;10(5):407-15.
1999: D Roger Illingworth
New risk factors for coronary heart disease.
The American journal of medicine 1999;107(2A):19S-21S.
1999: J R Guyton; Carlos A Dujovne; D Roger Illingworth
Dual hepatic metabolism of cerivastatin--clarifications.
The American journal of cardiology 1999;84(4):497.
1999: Evan A Stein; D Roger Illingworth; Peter O Kwiterovich; C A Liacouras; M A Siimes; Marc Jacobson; T G Brewster; P Hopkins; M Davidson; K Graham; F Arensman; Robert H Knopp; Carlos A Dujovne; C L Williams; Jonathan L Isaacsohn; CA Jacobsen; PM Laskarzewski; S Ames; GJ Gormley
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;281(2):137-44.
1998: J P O'Malley; Cheryl L Maslen; D Roger Illingworth
Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.
Circulation 1998;97(18):1780-3.
1998: Bruce R Gordon; S F Kelsey; P C Dau; A M Gotto; K Graham; D Roger Illingworth; Jonathan L Isaacsohn; P H Jones; S F Leitman; Stuart D Saal; Evan A Stein; T N Stern; A Troendle; R J Zwiener
Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group.
The American journal of cardiology 1998;81(4):407-11.
1998: P Barton Duell; William E Connor; D Roger Illingworth
Rhabdomyolysis after taking atorvastatin with gemfibrozil.
The American journal of cardiology 1998;81(3):368-9.
1997: Frederick J Raal; GJ Pilcher; D Roger Illingworth; Anuradha S Pappu; Evan A Stein; PM Laskarzewski; Yale B Mitchel; MR Melino
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
Atherosclerosis 1997;135(2):249-56.
1997: Michael H Davidson; Evan A Stein; Carlos A Dujovne; Donald B Hunninghake; Stuart R Weiss; Robert H Knopp; D Roger Illingworth; Yale B Mitchel; MR Melino; R V Zupkis; MR Dobrinska; R D Amin; Jonathan A Tobert
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
The American journal of cardiology 1997;79(1):38-42.
1996: Peter J H Jones; Anuradha S Pappu; L Hatcher; Z C Li; D Roger Illingworth; William E Connor
Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(10):1222-8.
1995: D Roger Illingworth; L F Hatcher; Anuradha S Pappu; K C Newcomb; William E Connor
Role of dietary cholesterol in the optimal diet for the treatment of hypercholesterolemia.
The Canadian journal of cardiology 1995;11 Suppl G():115G-117G.
1995: Cheryl L Maslen; D Babcock; D Roger Illingworth
Occurrence of a mutation associated with Wolman disease in a family with cholesteryl ester storage disease.
Journal of inherited metabolic disease 1995;18(5):620-3.
1994: Anuradha S Pappu; D Roger Illingworth
Diurnal variations in the plasma concentrations of mevalonic acid in patients with abetalipoproteinaemia.
European journal of clinical investigation 1994;24(10):698-702.
1994: D Roger Illingworth; Evan A Stein; Yale B Mitchel; Carlos A Dujovne; P H Frost; R H Knopp; P Tun; R V Zupkis; R A Greguski
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
Archives of internal medicine 1994;154(14):1586-95.
1994: D Roger Illingworth; J A Tobert
A review of clinical trials comparing HMG-CoA reductase inhibitors.
Clinical therapeutics 1994;16(3):366-85; discussion 365.
1994: Njeri Karanja; Cynthia Morris; P Rufolo; G Snyder; D Roger Illingworth; David A McCarron
Impact of increasing calcium in the diet on nutrient consumption, plasma lipids, and lipoproteins in humans.
The American journal of clinical nutrition 1994;59(4):900-7.
1994: Mogens Lytken Larsen; D Roger Illingworth; J P O'Malley
Comparative effects of gemfibrozil and clofibrate in type III hyperlipoproteinemia.
Atherosclerosis 1994;106(2):235-40.
1994: Mogens Lytken Larsen; D Roger Illingworth
Drug treatment of dyslipoproteinemia.
The Medical clinics of North America 1994;78(1):225-45.
1994: D Roger Illingworth
Therapeutic use of lovastatin in the treatment of hypercholesterolemia.
Clinical therapeutics 1994;16(1):2-26; discussion 1.
1993: D Roger Illingworth
How effective is drug therapy in heterozygous familial hypercholesterolemia?
The American journal of cardiology 1993;72(10):54D-58D.
1993: D Roger Illingworth
Lipoprotein metabolism.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1993;22(1):90-7.
1993: D Roger Illingworth; E B Schmidt
The influence of dietary n-3 fatty acids on plasma lipids and lipoproteins.
Annals of the New York Academy of Sciences 1993;676():60-9.
1993: E B Schmidt; D Roger Illingworth; S Bacon; S J Russell; S R Thatcher; R W Mahley; Karl H Weisgraber
Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100.
Metabolism: clinical and experimental 1993;42(2):137-9.
1993: E B Schmidt; D Roger Illingworth; S Bacon; R W Mahley; Karl H Weisgraber
Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100.
Atherosclerosis 1993;98(2):213-7.
1992: J S Prihoda; D Roger Illingworth
Drug therapy of hyperlipidemia.
Current problems in cardiology 1992;17(9):545-605.
1992: D Roger Illingworth; S Bacon; Anuradha S Pappu; G J Sexton
Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia.
Atherosclerosis 1992;96(1):53-64.
1992: D Roger Illingworth; F Vakar; R W Mahley; Karl H Weisgraber
Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100.
Lancet 1992;339(8793):598-600.
1991: J S Prihoda; Anuradha S Pappu; F E Smith; D Roger Illingworth
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
The Journal of clinical endocrinology and metabolism 1991;72(3):567-74.
1991: D Roger Illingworth
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Drugs 1991;41(2):151-60.
1990: D Roger Illingworth; R Cope; S P Bacon
Regression of tendon xanthomas in patients with familial hypercholesterolemia treated with lovastatin.
Southern medical journal 1990;83(9):1053-7.
1990: W S Harris; William E Connor; D Roger Illingworth; D W Rothrock; D M Foster
Effects of fish oil on VLDL triglyceride kinetics in humans.
Journal of lipid research 1990;31(9):1549-58.
1990: D Roger Illingworth
Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Clinical and investigative medicine. Médecine clinique et experimentale 1990;13(4):211-8.
1990: D Roger Illingworth; J P O'Malley
The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia.
Metabolism: clinical and experimental 1990;39(4):403-9.
1990: F C Hagemenas; Anuradha S Pappu; D Roger Illingworth
The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia.
European journal of clinical investigation 1990;20(2):150-7.
1990: W S Harris; D W Rothrock; A Fanning; S B Inkeles; S H Goodnight; D Roger Illingworth; William E Connor
Fish oils in hypertriglyceridemia: a dose-response study.
The American journal of clinical nutrition 1990;51(3):399-406.
1990: J P O'Malley; D Roger Illingworth
The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia.
Metabolism: clinical and experimental 1990;39(2):150-4.
1990: A Nordøy; D Roger Illingworth; William E Connor; S Goodnight
Increased activity of factor VII and factor VII-phospholipid complex measured using a Normotest system in subjects with hyperlipidemia.
Haemostasis 1990;20(2):65-72.
1989: D A Leaf; William E Connor; D Roger Illingworth; S P Bacon; G Sexton
The hypolipidemic effects of gemfibrozil in type V hyperlipidemia. A double-blind, crossover study.
JAMA : the journal of the American Medical Association 1989;262(22):3154-60.
1989: Anuradha S Pappu; D Roger Illingworth
Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
The Journal of laboratory and clinical medicine 1989;114(5):554-62.
1989: Anuradha S Pappu; D Roger Illingworth; S Bacon
Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.
Metabolism: clinical and experimental 1989;38(6):542-9.
1989: F C Hagemenas; D Roger Illingworth
Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
Arteriosclerosis (Dallas, Tex.) 1989;9(3):355-61.
1989: T A Golper; D Roger Illingworth; Cynthia Morris; W M Bennett
Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria.
American journal of kidney diseases : the official journal of the National Kidney Foundation 1989;13(4):312-20.
1989: D Roger Illingworth; Anuradha S Pappu; R E Gregg
Increased urinary mevalonic acid excretion in patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia.
Atherosclerosis 1989;76(1):21-7.
1989: D Roger Illingworth; S Bacon
Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Circulation 1989;79(3):590-6.
1989: D Roger Illingworth; William E Connor; L F Hatcher; W S Harris
Hypolipidaemic effects of n-3 fatty acids in primary hyperlipoproteinaemia.
Journal of internal medicine. Supplement 1989;731():91-7.
1989: D Roger Illingworth; S Bacon
Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Arteriosclerosis (Dallas, Tex.) 1989;9(1 Suppl):I121-34.
1988: W S Harris; William E Connor; N Alam; D Roger Illingworth
Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids.
Journal of lipid research 1988;29(11):1451-60.
1988: M A Lindner; D Roger Illingworth
Expression of type III hyperlipoproteinemia in an adolescent patient with hypothyroidism.
The Journal of pediatrics 1988;113(1 Pt 1):86-9.
1988: Anuradha S Pappu; D Roger Illingworth
Neutral lipid transfer activities in the plasma of patients with abetalipoproteinemia.
Atherosclerosis 1988;71(1):1-7.
1988: D Roger Illingworth; William E Connor; W S Harris
Hypolipidemic effects of dietary omega-3 fatty acids in humans.
Progress in clinical and biological research 1988;255():243-53.
1988: D Roger Illingworth
An overview of lipid-lowering drugs.
Drugs 1988;36 Suppl 3():63-71.
1988: D Roger Illingworth
Drug therapy of hypercholesterolemia.
Clinical chemistry 1988;34(8B):B123-32.
1987: F C Hagemenas; D Roger Illingworth
The influence of plasma lipoproteins from patients with abetalipoproteinemia on cellular cholesterol esterification.
Atherosclerosis 1987;68(1-2):105-9.
1987: D Roger Illingworth; S Bacon
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
The American journal of cardiology 1987;60(12):33G-42G.
1985: B E Phillipson; D W Rothrock; William E Connor; W S Harris; D Roger Illingworth
Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia.
The New England journal of medicine 1985;312(19):1210-6.
1984: W S Harris; William E Connor; S B Inkeles; D Roger Illingworth
Dietary omega-3 fatty acids prevent carbohydrate-induced hypertriglyceridemia.
Metabolism: clinical and experimental 1984;33(11):1016-9.